HRP20151004T1 - Farmaceutska nanosuspenzija - Google Patents
Farmaceutska nanosuspenzija Download PDFInfo
- Publication number
- HRP20151004T1 HRP20151004T1 HRP20151004TT HRP20151004T HRP20151004T1 HR P20151004 T1 HRP20151004 T1 HR P20151004T1 HR P20151004T T HRP20151004T T HR P20151004TT HR P20151004 T HRP20151004 T HR P20151004T HR P20151004 T1 HRP20151004 T1 HR P20151004T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- pharmaceutical suspension
- suspension according
- pharmaceutical
- surfactant
- Prior art date
Links
- 239000006070 nanosuspension Substances 0.000 title 1
- 239000007971 pharmaceutical suspension Substances 0.000 claims 15
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- 239000001361 adipic acid Substances 0.000 claims 3
- 235000011037 adipic acid Nutrition 0.000 claims 3
- 230000000507 anthelmentic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 claims 2
- 229960004500 flubendazole Drugs 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 claims 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 244000144977 poultry Species 0.000 claims 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 claims 2
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 claims 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 claims 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 229960002669 albendazole Drugs 0.000 claims 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 229940018602 docusate Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960005282 febantel Drugs 0.000 claims 1
- 229960005473 fenbendazole Drugs 0.000 claims 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229960003439 mebendazole Drugs 0.000 claims 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 229960004454 oxfendazole Drugs 0.000 claims 1
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 229960004546 thiabendazole Drugs 0.000 claims 1
- 239000004308 thiabendazole Substances 0.000 claims 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims 1
- 235000010296 thiabendazole Nutrition 0.000 claims 1
- MAZWDMBCPDUFDJ-UHFFFAOYSA-N trans-Traumatinsaeure Natural products OC(=O)CCCCCCCCC=CC(O)=O MAZWDMBCPDUFDJ-UHFFFAOYSA-N 0.000 claims 1
- MAZWDMBCPDUFDJ-VQHVLOKHSA-N traumatic acid Chemical compound OC(=O)CCCCCCCC\C=C\C(O)=O MAZWDMBCPDUFDJ-VQHVLOKHSA-N 0.000 claims 1
- 229960000323 triclabendazole Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Farmaceutska suspenzija koja sadrži surfaktant i kokristale nano-veličine najmanje jednog aktivnog sastojka i najmanje jednu dikarboksilnu kiselinu.
2. Farmaceutska suspenzija prema zahtjevu 1, naznačena time da je navedeni aktivni sastojak lijek slabo topiv u vodi.
3. Farmaceutska suspenzija prema zahtjevu 2, naznačena time da je navedeni lijek slabo topiv u vodi anthelminik; posebno anthelminik baziran na benzimidazolu.
4. Farmaceutska suspenzija prema zahtjevu 3, naznačena time da se anthelminik baziran na benzimidazolu bira iz popisa koji se sastoji od albendazola, mebendazola, tiabendazola, fenbendazola, febantela, oksfendazola, triclabendazola i flubendazola; posebno flubenzazol.
5. Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 4, naznačena time da se navedena dikarboksilna kiselina bira iz skupine koja se sastoji od oksalne kiseline, malonske kiseline, sukcinske kiseline, glutarne kiseline, adipinske kiseline, pimelinske kiseline, suberinske kiseline, azelaidne kiseline, sebazinske kiseline, undekandioične kiseline, dodekandioične kiseline, ftalne kiseline, izoftalne kiseline, tereftalne kiseline, maleinske kiseline, fumarne kiseline, glutakonske kiseline, traumatične kiseline i mukonske kiseline; posebno adipinske kiseline.
6. Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 5, naznačena time da se surfaktant bira iz popisa koji se sastoji od SDS (natrij dodecil sulfat), dokuzat, poloksameri, Triton X-100, Tween 20 i Tween 80; posebno Tween-80.
7. Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 6, naznačena time da sadrži kokristale nano-veličine flubendazola i adipinske kiseline.
8. Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 7, naznačena time da kokristali nano-veličine imaju prosječni promjer manji od 1μm.
9. Farmaceutski pripravak dobiven sušenjem farmaceutske suspenzije prema bilo kojem od patentnih zahtjeva 1 do 8.
10. Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski pripravak prema zahtjevu 9 za uporabu u humanoj ili veterinarskoj medicini.
11. Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski pripravak prema zahtjevu 9 za uporabu u liječenju parazitskih infekcija kod subjekta.
12. Uporaba dikarboksilne kiseline i surfaktanta za proizvodnju farmaceutske suspenzije prema bilo kojem od zahtjeva 1 do 8, ili farmaceutskog pripravka prema zahtjevu 9.
13. Farmaceutska suspenzija za uporabu prema zahtjevu 11, naznačena time da je subjekt izabran s popisa koji obuhvaća ljude, svinje, perad, goveda, ovce; posebno svinje i perad.
14. Postupak za proizvodnju farmaceutske suspenzije prema bilo kojem od zahtjeva 1 do 8; navedeni postupak obuhvaća:
dispergiranje najmanje jednog aktivnog sastojka, najmanje jedne dikarboksilne kiseline, i surfaktanta u vodi, i
mljevenje navedene disperzije.
15. Postupak za proizvodnju farmaceutskog pripravka prema zahtjevu 9; navedeni postupak obuhvaća:
dispergiranje najmanje jednog aktivnog sastojka, najmanje jedne dikarboksilne kiseline, i surfaktanta u vodi,
mljevenje navedene disperzije, i
sušenje farmaceutske suspenzije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11185803 | 2011-10-19 | ||
| PCT/EP2012/070617 WO2013057169A1 (en) | 2011-10-19 | 2012-10-18 | Pharmaceutical nanosuspension |
| EP12779018.6A EP2768485B1 (en) | 2011-10-19 | 2012-10-18 | Pharmaceutical nanosuspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151004T1 true HRP20151004T1 (hr) | 2015-11-20 |
Family
ID=47088845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151004TT HRP20151004T1 (hr) | 2011-10-19 | 2015-09-23 | Farmaceutska nanosuspenzija |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10251866B2 (hr) |
| EP (1) | EP2768485B1 (hr) |
| AU (1) | AU2012324911B2 (hr) |
| BR (1) | BR112014009242A8 (hr) |
| CA (1) | CA2852347C (hr) |
| DK (1) | DK2768485T3 (hr) |
| ES (1) | ES2548706T3 (hr) |
| HR (1) | HRP20151004T1 (hr) |
| HU (1) | HUE027923T2 (hr) |
| PL (1) | PL2768485T3 (hr) |
| SI (1) | SI2768485T1 (hr) |
| TW (1) | TWI580442B (hr) |
| WO (1) | WO2013057169A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016140219A1 (ja) * | 2015-03-02 | 2016-09-09 | 武田薬品工業株式会社 | ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法 |
| EP3170817A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Co-crystals of benzimidazole compounds |
| CN108403646B (zh) * | 2018-04-08 | 2021-04-20 | 新疆医科大学第一附属医院 | 阿苯达唑纳米微粉及其制备方法 |
| CN113318079B (zh) * | 2021-05-13 | 2024-01-09 | 江西博莱大药厂有限公司 | 一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法 |
| CN114224834B (zh) * | 2021-12-24 | 2022-11-11 | 沈阳伟嘉生物技术有限公司 | 一种具有较高生物利用度的阿苯达唑纳米混悬剂及其制备方法 |
| CN117462491A (zh) * | 2023-11-26 | 2024-01-30 | 江西省保灵动物保健品有限公司 | 一种阿苯达唑混悬液及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5932544A (en) | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
| WO2004078163A2 (en) * | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| ITMI20021074A1 (it) | 2002-05-20 | 2003-11-20 | Actimex S R L | Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione |
| EP1742941A1 (en) * | 2004-04-22 | 2007-01-17 | Transform Pharmaceuticals, Inc. | Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| CA2621800A1 (en) | 2005-09-06 | 2007-03-15 | Astellas Pharma Inc. | Fine particles of poorly soluble drug having enteric base material adsorbed on the surface thereof |
| NZ599069A (en) * | 2006-06-30 | 2013-10-25 | Iceutica Pty Ltd | Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form |
| KR20110098012A (ko) * | 2007-02-09 | 2011-08-31 | 화이자 리미티드 | 구충제 |
| US20100204204A1 (en) * | 2007-06-06 | 2010-08-12 | University Of South Florida | Nutraceutical co-crystal compositions |
| US20110268775A1 (en) | 2009-01-06 | 2011-11-03 | Pharmanova, Inc. | Nanoparticle pharmaceutical formulations |
| WO2011036676A2 (en) | 2009-09-23 | 2011-03-31 | Ashwini Nangia | Stable cocrystals of temozolomide |
-
2012
- 2012-10-16 TW TW101138015A patent/TWI580442B/zh active
- 2012-10-18 DK DK12779018.6T patent/DK2768485T3/en active
- 2012-10-18 EP EP12779018.6A patent/EP2768485B1/en active Active
- 2012-10-18 SI SI201230316T patent/SI2768485T1/sl unknown
- 2012-10-18 PL PL12779018T patent/PL2768485T3/pl unknown
- 2012-10-18 ES ES12779018.6T patent/ES2548706T3/es active Active
- 2012-10-18 WO PCT/EP2012/070617 patent/WO2013057169A1/en active Application Filing
- 2012-10-18 HU HUE12779018A patent/HUE027923T2/en unknown
- 2012-10-18 CA CA2852347A patent/CA2852347C/en active Active
- 2012-10-18 US US14/352,154 patent/US10251866B2/en active Active
- 2012-10-18 BR BR112014009242A patent/BR112014009242A8/pt not_active Application Discontinuation
- 2012-10-18 AU AU2012324911A patent/AU2012324911B2/en active Active
-
2015
- 2015-09-23 HR HRP20151004TT patent/HRP20151004T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014009242A2 (pt) | 2017-06-13 |
| CA2852347C (en) | 2020-06-30 |
| AU2012324911B2 (en) | 2016-09-15 |
| TWI580442B (zh) | 2017-05-01 |
| PL2768485T3 (pl) | 2015-12-31 |
| WO2013057169A1 (en) | 2013-04-25 |
| EP2768485B1 (en) | 2015-07-22 |
| TW201323013A (zh) | 2013-06-16 |
| ES2548706T3 (es) | 2015-10-20 |
| EP2768485A1 (en) | 2014-08-27 |
| US10251866B2 (en) | 2019-04-09 |
| BR112014009242A8 (pt) | 2017-06-20 |
| US20140255498A1 (en) | 2014-09-11 |
| SI2768485T1 (sl) | 2015-12-31 |
| CA2852347A1 (en) | 2013-04-25 |
| AU2012324911A1 (en) | 2014-05-22 |
| DK2768485T3 (en) | 2015-10-05 |
| HUE027923T2 (en) | 2016-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151004T1 (hr) | Farmaceutska nanosuspenzija | |
| RU2018115574A (ru) | Полимерные композиты, полученные по способу золь-гель, и их применение | |
| PE20171308A1 (es) | Forma de dosificacion que incluye una solucion solida de drogas amorfas | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| BR122019027412B8 (pt) | composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração | |
| BR112014024833A8 (pt) | Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia. | |
| MA41496A (fr) | Compositions pharmaceutiques comprenant la n-(3,5-diméthoxyphényl)-n'-(1-méthyléthyl)-n-[3-(1-méthyl-1h-pyrazol-4-yl)quinoxalin-6-yl]éthane-1,2-diamine | |
| JP2016027060A5 (hr) | ||
| SI3189830T1 (en) | FORMULATION OF THE MEDICINAL PRODUCT WITH LOWER REMEDY | |
| JP2017222722A5 (hr) | ||
| MX2018002627A (es) | Metodo de cristalizacion y biodisponibilidad. | |
| MX2021010359A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| HRP20240197T1 (hr) | Farmaceutski pripravak koji sadrži protuvirusni derivat dihidrokinazolina koji ima konfiguraciju s na položaju 4 | |
| JP2009544665A5 (hr) | ||
| AR108729A1 (es) | Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico | |
| CL2018003682A1 (es) | Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos. | |
| JP2016534062A5 (hr) | ||
| PE20091900A1 (es) | Una formulacion farmaceutica solida | |
| JP2017523149A5 (hr) | ||
| Algin-Yapar | Nasal inserts for drug delivery: an overview | |
| EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине | |
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
| HRP20150387T1 (hr) | Sol kolina i trometamina od likofelona | |
| JP2016515517A5 (hr) | ||
| SI2533774T1 (en) | APPLICATION OF AGOMELATINES FOR PREPARATION OF MEDICINAL PRODUCTS FOR TREATMENT OF A VITAL COMPULSIVE DISEASE (OKM) |